FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274898491> ?p ?o ?g. }

• W2274898491 abstract "Toll-like receptors (TLRs) play an important role in the innate and adaptive immune responses to pathogens, and are the target of new vaccine adjuvants. TLR2 plays a role in parasite recognition and activation of immune responses during cutaneous leishmaniasis infection, suggesting that TLR2 could be targeted by adjuvants for use in Leishmania vaccines. We therefore explored using Pam2CSK4 (Pam2) and Pam3CSK4 (Pam3) lipopeptide adjuvants, which activate TLR2/6 and TLR2/1 heterodimers respectively, in vaccine models for parasitic infections. The use of lipopeptide adjuvants was explored using two vaccine models. For cutaneous leishmaniasis, the lipopeptide adjuvants Pam2 and Pam3 were compared to that of the Th1-driving double-stranded DNA TLR9 agonist CpG for their ability to improve the efficacy of the autoclaved Leishmania major (ALM) vaccine to protect against L. major infection. The ability of Pam2 to enhance the efficacy of a soluble Brugia malayi microfilariae extract (BmMfE) vaccine to protect against filarial infection was also assessed in a peritoneal infection model of B. malayi filariasis. Parasite antigen-specific cellular and humoral immune responses were assessed post-challenge. The use of lipopeptides in ALM-containing vaccines did not provide any protection upon infection with L. major, and Pam2 exacerbated the disease severity in vaccinated mice post-challenge. Pam2, and to a lesser extent Pam3, were able to elevate antigen-specific immune responses post-challenge in this model, but these responses displayed a skewed Th2 phenotype as characterised by elevated levels of IgG1. In the B. malayi vaccine model, the use of Pam2 as an adjuvant with BmMfE induced significant protective immunity to the same level as inclusion of an Alum adjuvant. Here, both Pam2 and Alum were found to enhance antigen-specific antibody production post-challenge, and Pam2 significantly elevated levels of antigen-specific IL-4, IL-5 and IL-13 produced by splenocytes. These data indicate that TLR2/6-targeting ligands could be considered as adjuvants for vaccines that require robust Th2 and/or antibody-dependent immunity." @default.
• W2274898491 created "2016-06-24" @default.
• W2274898491 creator A5026086885 @default.
• W2274898491 creator A5036038273 @default.
• W2274898491 creator A5052953199 @default.
• W2274898491 creator A5054668376 @default.
• W2274898491 creator A5056925040 @default.
• W2274898491 date "2016-02-20" @default.
• W2274898491 modified "2023-09-27" @default.
• W2274898491 title "The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models" @default.
• W2274898491 cites W1486895457 @default.
• W2274898491 cites W1530482090 @default.
• W2274898491 cites W1638612717 @default.
• W2274898491 cites W1878522445 @default.
• W2274898491 cites W1953262024 @default.
• W2274898491 cites W1969345280 @default.
• W2274898491 cites W1975262958 @default.
• W2274898491 cites W1978511113 @default.
• W2274898491 cites W1979991507 @default.
• W2274898491 cites W1980775088 @default.
• W2274898491 cites W1982932318 @default.
• W2274898491 cites W1985190174 @default.
• W2274898491 cites W1995545582 @default.
• W2274898491 cites W1997320239 @default.
• W2274898491 cites W1997626690 @default.
• W2274898491 cites W2002626580 @default.
• W2274898491 cites W2012813469 @default.
• W2274898491 cites W2012924662 @default.
• W2274898491 cites W2013352196 @default.
• W2274898491 cites W2013887826 @default.
• W2274898491 cites W2017016035 @default.
• W2274898491 cites W2021627528 @default.
• W2274898491 cites W2028682232 @default.
• W2274898491 cites W2033849626 @default.
• W2274898491 cites W2042728718 @default.
• W2274898491 cites W2050368040 @default.
• W2274898491 cites W2066648696 @default.
• W2274898491 cites W2069151296 @default.
• W2274898491 cites W2071461046 @default.
• W2274898491 cites W2077025077 @default.
• W2274898491 cites W2083613729 @default.
• W2274898491 cites W2085613205 @default.
• W2274898491 cites W2096210882 @default.
• W2274898491 cites W2096729904 @default.
• W2274898491 cites W2102500641 @default.
• W2274898491 cites W2104045394 @default.
• W2274898491 cites W2109245565 @default.
• W2274898491 cites W2109988364 @default.
• W2274898491 cites W2111717604 @default.
• W2274898491 cites W2113240161 @default.
• W2274898491 cites W2115569719 @default.
• W2274898491 cites W2117534618 @default.
• W2274898491 cites W2120081315 @default.
• W2274898491 cites W2120393810 @default.
• W2274898491 cites W2127136381 @default.
• W2274898491 cites W2128320197 @default.
• W2274898491 cites W2144887013 @default.
• W2274898491 cites W2145926064 @default.
• W2274898491 cites W2148267961 @default.
• W2274898491 cites W2153485954 @default.
• W2274898491 cites W2156575228 @default.
• W2274898491 cites W2165782913 @default.
• W2274898491 cites W2169197943 @default.
• W2274898491 cites W2170319274 @default.
• W2274898491 cites W2170732329 @default.
• W2274898491 cites W2172279071 @default.
• W2274898491 cites W2177385981 @default.
• W2274898491 doi "https://doi.org/10.1186/s13071-016-1381-0" @default.
• W2274898491 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4761161" @default.
• W2274898491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26897363" @default.
• W2274898491 hasPublicationYear "2016" @default.
• W2274898491 type Work @default.
• W2274898491 sameAs 2274898491 @default.
• W2274898491 citedByCount "37" @default.
• W2274898491 countsByYear W22748984912017 @default.
• W2274898491 countsByYear W22748984912018 @default.
• W2274898491 countsByYear W22748984912019 @default.
• W2274898491 countsByYear W22748984912020 @default.
• W2274898491 countsByYear W22748984912021 @default.
• W2274898491 countsByYear W22748984912022 @default.
• W2274898491 countsByYear W22748984912023 @default.
• W2274898491 crossrefType "journal-article" @default.
• W2274898491 hasAuthorship W2274898491A5026086885 @default.
• W2274898491 hasAuthorship W2274898491A5036038273 @default.
• W2274898491 hasAuthorship W2274898491A5052953199 @default.
• W2274898491 hasAuthorship W2274898491A5054668376 @default.
• W2274898491 hasAuthorship W2274898491A5056925040 @default.
• W2274898491 hasBestOaLocation W22748984911 @default.
• W2274898491 hasConcept C136449434 @default.
• W2274898491 hasConcept C147483822 @default.
• W2274898491 hasConcept C159047783 @default.
• W2274898491 hasConcept C165901193 @default.
• W2274898491 hasConcept C203014093 @default.
• W2274898491 hasConcept C2775848585 @default.
• W2274898491 hasConcept C2777425210 @default.
• W2274898491 hasConcept C2777629521 @default.
• W2274898491 hasConcept C2777863537 @default.
• W2274898491 hasConcept C2781236682 @default.
• W2274898491 hasConcept C523546767 @default.
• W2274898491 hasConcept C54355233 @default.

• next